Digestive System TRIZ Cases

Extracted thylakoids regulate gut microbiota by increasing insulin sensitivity and enhancing probiotic adherence to the mucosa.

A Lactobacillus composition inhibits Helicobacter pylori adhesion and invasion through bacterial competition.

Anti-EMR1 antibodies bind the ELD-6 receptor domain to deplete eosinophils, addressing the lack of selective binding in existing therapies.

Hydrated food-grade polymers form non-particulate matrices that sustain warming sensations across the throat without causing stinging.

A subcutaneously implanted pump delivers levodopa and carbidopa using a high-concentration, low-viscosity solvent system.

A polymeric film coating combines water-insoluble polymer and indigestible polysaccharide to control drug release kinetics.

Substituted perhydro pyrrolopyridines decrease viral load to address inadequate sustained response rates and side effects of current therapies.

Specific amino acid substitutions reduce immunogenicity and enable targeted treatment of intestinal fibrosis in severe inflammatory bowel disease.

Thermo-sensitive gel coatings shield probiotic bacteria from heat and humidity, preserving viability in liquid food products.

Optimized amino acid sequences boost BMP receptor interaction, shortening osteointegration periods and improving implant success rates.

Segmenting homing moieties from therapeutic agents resolves the contradiction between efficacy and side effects in sepsis treatment.

Crystalline tromethamine and choline salts of a potent HCV inhibitor resolve amorphous instability and variable hydrate challenges.

In vitro screening of probiotic strains based on measured gas volume reduction identifies specific microbial compositions that minimize bloating symptoms.

Antigen-antibody binding directs kinase inhibitors to activated hepatic stellate cells, reducing off-target toxicity.

A glutathione-based pharmaceutical composition targets fat deposition in the liver to prevent nonalcoholic fatty liver disease progression.

Staged pH adjustment during crossflow filtration reduces lipid hydrolysis byproducts and increases final product volume.

A glucomannan and chitosan composition forms a physical barrier to modulate gastric acidity.

Gliclazide targets TRPC6 channels to suppress autophagy in hepatic stellate cells, addressing poor efficacy of current anti-fibrosis therapies.

Neutralizing Acyl-CoA binding protein with a monoclonal antibody activates autophagy, preventing liver fibrosis and tissue damage.

Autologous adipose-derived regenerative cells bypass expensive transplantation by promoting angiogenesis and anti-fibrosis to maintain hepatic function.

Attaching exogenous cell membranes to outer mitochondrial membranes stabilizes biological activity and enhances therapeutic effects on dysfunction.

RBC-derived exosome mimetics provide targeted drug delivery by eliminating complex purification steps required for natural exosomes.

Administering specific bacterial strains restores healthy gut flora, addressing gastrointestinal complications caused by enzyme replacement therapy.

A skeletal myoblast composition delivers cytokines to stimulate liver cell proliferation and tissue repair.

P-anisaldehyde replaces capsaicin to provoke swallowing via TRPA1 activation, avoiding burning sensations and toxic side effects.

Replacing GLUT1 with ASCT2 biomarkers resolves detection specificity issues in medical imaging.

Combining TLR3 and FXR agonists activates innate immunity to increase interferon production.

Acetate buffer and Polysorbate 80 stabilize anti-HER2 antibodies, preventing aggregation during storage and freeze-thaw cycles.

Modified oligonucleotides bind specific microRNAs to inhibit cancer cell proliferation and induce apoptosis in liver tumors.

Serp-1 peptide polypeptides maintain protective gut microbiota composition during gammaherpesvirus infection.

Encapsulated beta-hydroxybutyrate in PLGA nanoparticles sustains intestinal stemness and promotes regeneration of Lgr5+ cells after radiation-induced damage.

Co-cultivated bacterial consortia restore gut microbiome balance through controlled fermentation of specific strains.

Reducing D,L-PLA molecular weight below 60,000 Daltons accelerates hydrolysis absorption while maintaining structural integrity during sterilization.

Tiglic aldehyde activates the TRPA1 cation channel to provoke the swallowing reflex in dysphagic patients.

A colonic release tablet disperses turmeric, pomegranate, and Boswellia extracts in a sodium alginate and hydroxypropyl methylcellulose matrix.

Antibodies targeting specific glycosylation sites on pancreatic ribonuclease 1 resolve low specificity issues in conventional serum markers.

A transdermal scopolamine patch uses an adhesive skin contact layer to dissolve and release the active ingredient directly through the skin.

Bispecific antibody conjugates bind epidermal growth factor receptor and c-Met to overcome drug resistance while minimizing toxicity to normal tissues.

Engineered Lactococcus lactis bacteria shield ISVD fragments from gastrointestinal degradation, enabling effective oral delivery of TNF binders.

Combining ASK1 inhibition with FXR activation targets apoptotic signaling and bile acid metabolism.

Administering vitamin C and K reduces NFκB production to manage inflammation and extend implant longevity.

Kynurenic acid modulates matrix metalloproteinase and collagen levels to resolve extracellular matrix accumulation in keloids.

Oral lubabegron administration reduces ammonia and carbon dioxide emissions while preserving muscle accumulation and meat quality.

Phosphorylated MLKL biomarker enables precise identification of oral neoplastic lesions, addressing low diagnostic reliability in early detection.